Abstract
Metabolic syndrome (MetS) is a leading public health and clinical challenge worldwide. MetS represents a group of interrelated risk factors that predict cardiovascular diseases (CVD) and diabetes mellitus (DM). Its prevalence ranges between 10 and 84%, depending on the geographic region, urban or rural environment, individual demographic characteristics of the population studied (sex, age, racial and ethnic origin), as well as the criteria used to define MetS. Persons with MetS have higher mortality rate when compared with people without MetS, primarily caused by progressive atherosclerosis, accelerated by pro-inflammatory and pro-coagulation components of MetS. Considering the high prevalence of metabolic disorders (glucose metabolism disorder, hypertension, dyslipidaemia, obesity etc.), preventive healthcare should focus on changing lifestyle in order to reduce obesity and increase physical activity. This narrative review considers the available evidence from clinical and experimental studies dealing with MetS, and current treatment options for patients with insulin resistance and MetS.
Keywords: Metabolic syndrome, insulin resistance, cardiovascular disease.
Graphical Abstract
Current Vascular Pharmacology
Title:Link between Metabolic Syndrome and Insulin Resistance
Volume: 15 Issue: 1
Author(s): Zoran Gluvic, Bozidarka Zaric, Ivana Resanovic, Milan Obradovic, Aleksandar Mitrovic, Djordje Radak and Esma R. Isenovic
Affiliation:
Keywords: Metabolic syndrome, insulin resistance, cardiovascular disease.
Abstract: Metabolic syndrome (MetS) is a leading public health and clinical challenge worldwide. MetS represents a group of interrelated risk factors that predict cardiovascular diseases (CVD) and diabetes mellitus (DM). Its prevalence ranges between 10 and 84%, depending on the geographic region, urban or rural environment, individual demographic characteristics of the population studied (sex, age, racial and ethnic origin), as well as the criteria used to define MetS. Persons with MetS have higher mortality rate when compared with people without MetS, primarily caused by progressive atherosclerosis, accelerated by pro-inflammatory and pro-coagulation components of MetS. Considering the high prevalence of metabolic disorders (glucose metabolism disorder, hypertension, dyslipidaemia, obesity etc.), preventive healthcare should focus on changing lifestyle in order to reduce obesity and increase physical activity. This narrative review considers the available evidence from clinical and experimental studies dealing with MetS, and current treatment options for patients with insulin resistance and MetS.
Export Options
About this article
Cite this article as:
Gluvic Zoran, Zaric Bozidarka, Resanovic Ivana, Obradovic Milan, Mitrovic Aleksandar, Radak Djordje and Isenovic R. Esma, Link between Metabolic Syndrome and Insulin Resistance, Current Vascular Pharmacology 2017; 15 (1) . https://dx.doi.org/10.2174/1570161114666161007164510
DOI https://dx.doi.org/10.2174/1570161114666161007164510 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phytochemical Genistein in the Regulation of Vascular Function: New Insights
Current Medicinal Chemistry Obesity and Oxidative Stress: Potential Roles of Melatonin as Antioxidant and Metabolic Regulator
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera
Recent Patents on Biotechnology Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
Current Pharmaceutical Design Potential Interaction Between Valproic Acid and Doripenem
Current Drug Safety Meet Our Editorial Board Member
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Phytochemicals as Prototypes for Pharmaceutical Leads Towards Drug Development Against Diabetic Cardiomyopathy
Current Pharmaceutical Design Antioxidants in the Treatment of Diabetes
Current Diabetes Reviews Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Adipocytokines; Cause for Metabolic Syndrome
Current Medicinal Chemistry - Central Nervous System Agents Monoclonal Antibodies in the Management of Solid Tumors
Current Topics in Medicinal Chemistry History and Global Status of the New Coronavirus Covid-2019 and Aspects of Previous Infections of SARS-CoV and MERS-CoV: A Systematic Review
Coronaviruses Dose-related Effects of Resveratrol in Different Models of Pulmonary Arterial Hypertension: A Systematic Review
Current Cardiology Reviews Combination Therapy with Chinese Medicine and ACEI/ARB for the Management of Diabetic Nephropathy: The Promise in Research Fragments
Current Vascular Pharmacology The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Calcium Pattern Assessment in Patients with Severe Aortic Stenosis Via the Chou’s 5-Steps Rule
Current Pharmaceutical Design Mitochondrion as a Selective Target for the Treatment of Atherosclerosis: Role of Mitochondrial DNA Mutations and Defective Mitophagy in the Pathogenesis of Atherosclerosis and Chronic Inflammation
Current Neuropharmacology Intestinal Permeability in Non-alcoholic Fatty LIVER Disease: The Gut-liver Axis
Reviews on Recent Clinical Trials Management of Hypertension in the Acute Phase of Stroke
Current Hypertension Reviews